Posts Tagged ‘B-Raf inhibitor’:

Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with unique driver mutations.

Niehr F, von Euw E, Attar N, Guo D, Matsunaga D, Sazegar H, Ng C, Glaspy JA, Recio JA, Lo RS, Mischel PS, Comin-Anduix B, Ribas A. “J Transl Med. 2011 May ” BACKGROUND: A molecular linkage in between the MAPK and also the LKB1-AMPK power sensor pathways suggests that blended MAPK oncogene inhibition and

(Read More…)

several immunotherapeutic and targeted agents for the treatment of melanoma.

Natarajan N, Telang S, Miller D, Chesney J. “Drugs. 2011 Jul” Phenomenon: Melanoma incidence is increasing each year and over 40,000 die of this illness each year worldwide. In this assessment, we talk about the rationale and recent trial results of many novel immunotherapeutic strategies and modest molecule inhibitors of signalling kinases. Solutions: Ipilimumab is

(Read More…)

B-Raf fusion Protein Associated to c-Met Drug Resistance

Dillon R, Nilsson C, Shi SD, Lee N, Krastins B, Greig MJ. “J Proteome Res. 2011 Sep” In recent years there happen to be notable improvements using the growth of anti-cancer medication including those targeting protein tyrosine kinases such as the c-Met receptor, which is implicated in the development and progression of a number of

(Read More…)

© Apoptosis|apoptosis inhibitor|apoptosis pathway